Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
Agustí Barnadas, Silvia M. Vidal, Margarita Majem, Leticia Alserawan, Mariona Riudavets, Carlos Zamora, Jorgina Serra, Andrés Barba, Javier Gavira, Pablo Gallardo, M. Angels Ortiz, Georgia Anguera, Lidia Perea, Ivana Sullivan
Publikováno v:
CANCER IMMUNOLOGY IMMUNOTHERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background Anti-PD-(L)1 blocking agents can induce immune-related adverse events (irAEs), which can compromise treatment continuation. Since circulating leukocyte-platelet (PLT) complexes contribute to inflammatory and autoimmune diseases, we aimed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e09d11d6e57947dc938268b24327bc5
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5108
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5108
Autor:
Elisabeth G. Klompenhouwer, Annouschka Laenen, Kevin Punie, Regina G. H. Beets-Tan, Patrick Neven, B. M. Aarts, Geert Maleux, Hans Wildiers, Raphaëla Dresen
Publikováno v:
Breast Cancer Research and Treatment, 176(3), 597-605. Springer, Cham
PURPOSE: The aim of this study was to determine the safety and efficacy of Mitomycin C (MMC) infusion in a large cohort of advanced liver metastatic breast cancer patients (LMBC) and to determine factors influencing overall survival (OS). METHODS: We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::204b911c0d956ca18fc1c6cfe1108c7c
https://lirias.kuleuven.be/handle/123456789/640306
https://lirias.kuleuven.be/handle/123456789/640306
Autor:
J.M. Velarde, Pilar Teixidor, Christian de Quintana, Gerard Plans, Josep Maria Mesquida González, Rocio Diaz, Jaume Capellades, Carmen Balana, Laura Oleaga, Teresa Pujol, Angels Camins, Gerard Conesa, Sira Domenech, Carles Majós, Josep Puig, Natalia García-Balañà
Publikováno v:
JOURNAL OF NEURO-ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Journal of Neuro-Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Journal of Neuro-Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
To assess the value of resection in glioblastoma based on pre-surgical tumor characteristics and a subsequent staging system. The lack of a staging system for glioblastoma hinders the analysis of treatment outcome. We classified 292 uniformly treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d48e873d7d62fe256b5d061b9ae83f54
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3758
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3758
Autor:
Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria I, Lacalle A, Visa L, Rodríguez Palomo A, Mangas M, Cano JM, Buxo E, Álvarez-Manceñido F, García T, Lorenzo JE, Ferrer-Cardona M, Viudez A, Azkarate A, Ramchandani A, Arias D, Longo F, López C, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Fernández Montes A, Sala P, Cerdá P, Rivera F, Gallego J, AGAMENON study group
Publikováno v:
Gastric Cancer
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Although anthracycline-based triplets are one of the most widely used schedules to treat advanced gastric cancer (AGC), the benefit of including epirubicin in these therapeutic combinations remains unknown. This study aims to evaluate both the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f3d92d4953160cc76bd58c743d53ed
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7086
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7086
Publikováno v:
Europe PubMed Central
Cancer Chemotherapy and Pharmacology, 51(2), 167-173. SPRINGER
Cancer Chemotherapy and Pharmacology, 51(2), 167-173. SPRINGER
Purpose: The influence of liver metastases on the pharmacokinetics of 5-fluorouracil (5-FU) and its metabolite 5,6-dihydrofluorouracil (DHFU) was studied in patients with liver metastases from gastrointestinal cancer (n = 16) and compared with a cont
Publikováno v:
International Journal of Colorectal Disease; 28(11), pp 1479-1487 (2013)
BACKGROUND: Accumulating data suggest a role of chemokines in tumor cell metastasis. CCR4 has been implicated in hematologic malignancies and recently also in solid tumors. Herein, we hypothesized that CCR4 might be expressed and support migration of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e7a6c62675da010ddb18acc1ec515e
http://lup.lub.lu.se/record/3804839
http://lup.lub.lu.se/record/3804839
Autor:
Lucia Mentuccia, E. Fontana, Marco Merlano, Lisa Salvatore, Alfredo Falcone, Lorenzo Fornaro, Fotios Loupakis, Stefano Cascinu, Giacomo Allegrini, Michele Andreuccetti, Enrico Cortesi, Gianluca Masi, Enrico Vasile, Cristina Granetto
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2010, 66 (3), pp.559-566. ⟨10.1007/s00280-009-1196-1⟩
Università di Pisa-IRIS
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2010, 66 (3), pp.559-566. ⟨10.1007/s00280-009-1196-1⟩
Università di Pisa-IRIS
5-Fluorouracil (5-FU) plus cisplatin (C) can be considered a standard option for advanced gastric cancer (AGC). Irinotecan (Ir) and docetaxel (D) are active agents with no complete cross-resistance with C and 5-FU. Concomitant combination of Ir or D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6708f1901ced4af56244c112599cf09
http://hdl.handle.net/11573/80795
http://hdl.handle.net/11573/80795